There are 750,000 people in the U.K., and more than six million Americans suffering from Alzheimer's. Laconomab is ahead in the commercialization process; it has a list price of $26,000 a year. The feeling is that Donanomab will get FDA approval before the end of this year. Blood tests are being developed to show whether or not you've got Alzheimer's.